46. 悪性関節リウマチ
[臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03852355
(ClinicalTrials.gov)
February 25, 201922/2/2019the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritisthe Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis; a Randomized Controlled TrialRheumatoid Arthritis;HeadacheDrug: Radiofrequency;Drug: SteroidsAssiut UniversityNULLCompleted18 Years60 YearsAll60N/AEgypt
2NCT01287533
(ClinicalTrials.gov)
April 201030/1/2011Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term SteroidsEfficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term GlucocorticoidsRheumatoid Arthritis;Osteoporosis;OsteopeniaDrug: Ibandronate;Drug: PlaceboYeong-Wook SongNULLCompleted18 Years75 YearsFemale167Phase 4Korea, Republic of
3NCT00233558
(ClinicalTrials.gov)
June 200513/9/2005Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid ArthritisMulticentre, Randomised, Open Label Study Comparing a Scheduled Steroid Reduction Strategy” Versus a Free Steroid Reduction Strategy (Physician’s Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 MonthsRheumatoid ArthritisDrug: adalimumab (up to 9 months exposure);Drug: methotrexateAbbottNULLTerminated18 YearsN/ABoth160Phase 4United States